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We studied the peripheral representation, in vitro expan-
sion, cytokine production, and cytotoxicity of cd T
lymphocytes from 23 patients with cutaneous primary
melanoma and 28 healthy subjects. We demonstrated
that the absolute number and the percentage of circulat-
ing cdþ Tcells were signi¢cantly reduced in melanoma
patients in comparison with healthy subjects. The de-
crease was due to a reduction of Vd2 T cells, whereas
the number of Vd1 Tcells was not a¡ected. As a conse-
quence, the Vd2/Vd1 ratio was inverted in melanoma
patients. A lower percentage of cdþ T cells producing
tumor necrosis factor-a or interferon-c was found in
melanoma patients. After a 10 d in vitro culture, both
the percentage and the expansion index of cd T cells,
and in particular of Vd2 subset, were signi¢cantly re-
duced in melanoma patients in comparison with
healthy subjects. The cytotoxicity of sorted cd T cells
against tumor cell lines and the percentage of cd Tcells
producing perforins were preserved in melanoma pa-
tients. The numerical and functional impairment of cd
T cells could contribute to the inadequate immune re-
sponse found in melanoma patients and o¡ers the
potentiality for the planning of new approaches of
immune therapy of malignant melanoma. Key words:
£uorescence-activated cell sorter/human/melanoma/tumor
immunity/cd Tcells J Invest Dermatol 120:829 ^834, 2003
V
arious clinical and experimental observations point
to the existence of an immunologic host defense in
cutaneous malignant melanoma. CD3þ T cell re-
ceptor (TCR) a/b-expressing lymphocytes are con-
sidered the prevailing lymphocyte subset in primary
as well as secondary malignant melanoma (Strohal et al, 1994).
Immunomodulatory therapies with cytokines or adoptive trans-
fer of T cells have accomplished complete or partial tumor re-
gression in melanoma patients. Nevertheless, the immune
response is in most cases inadequate to control tumor growth as
tumor progression often occurs (Lee et al, 1999; Dudley et al,
2001). Hence, the coexistence of a cellular immune response in
melanoma lesions (Kammala et al, 1999), demonstrated by the
presence of clonally expanded T cells, and the inability of mela-
noma-speci¢c killer T cells to arrest tumor growth, remains
a major paradox of tumor immunology (Thor Straten et al, 1999;
Nielsen et al, 2000).
T lymphocytes bearing the gdTCR represent a minor popula-
tion of human peripheral lymphocytes (1^10%) the majority of
them expressing the Vd9/Vd2 TCR and the CD3þCD4^CD8^
phenotype (Groh et al, 1989; Poccia et al, 1998). The second most
frequent subset of peripheral blood gd Tcells expresses Vd1 in as-
sociation with various Vg elements. The ability of gd T cells to
respond to nonprocessed and nonpeptidic phosphoantigens in a
major histocompatibility complex (MHC)-unrestricted manner
are important features distinguishing them from ab T cells
(Brenner et al, 1987; Bukowski et al, 1995). gdTcells are activated by
mycobacterial antigens, such as isopentenyl pyrophosphate (IPP)
and related phenyl pyrophosphate derivatives (Costant et al, 1994;
Tanaka et al, 1995; Burk et al, 1995), stress-associated heat shock
proteins (Fisch et al, 1999), as well as by several cytokines, such as
interleukin (IL)-2 (Kjeldsen-Kragh et al, 1993), IL-12 (Fujimiya
et al, 1997), or tumor necrosis factor (TNF)-a (Ueta et al, 1996;
Lahn et al, 1998). Other signals, such as MHC class I-related chains
A and B, are able to engage the activating receptor, NKG2D, pre-
sent on Vd2 T cells, substantially enhancing the TCR-dependent
Vd2 T cell response to nonpeptide antigens (Das et al, 2001; Wu
et al, 2002). Although little is known about the physiologic sig-
ni¢cance of gd T cells, their marked reactivity toward mycobac-
terial and parasitic antigens, as well as tumor cells, suggests that
gd T cells play a part in the anti-infectious and anti-tumoral im-
mune surveillance (Poccia et al, 1998; Zheng et al, 2001). gdTcells
may contribute to the immune defense against cancer, having at
least two important functions, i.e., reactivity to tumor cells, and
regulatory interactions with abT cells (Kabelitz et al, 1999). gd T
cells strongly react against certain lymphoma cells, such as Daudi
cells, suggesting a cross-reactivity between microbial and tumor-
associated antigens (Kunzmann et al, 2000). Furthermore, gd T
cells have been identi¢ed among tumor-in¢ltrating lymphocytes
in various cancer types (Kabelitz et al, 2000). Once activated, gdT
cells produce high levels of cytokines and, mainly, IFN-g and
TNF-a (Poccia et al, 1997). Mainly because of their cytokine pro-
duction, gdTcells have been proposed to be involved in co-ordi-
nating the interplay between innate and acquired immunity and,
in particular, to guide the establishment of acquired immunity
contributing to select appropriate antigens and the strategies for
their elimination, and to the de¢nition of ab T cell responses1Equally contributed to this work.
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toward T helper (Th) 1 or Th2 phenotype (Fearon and Locksley,
1996; Mak and Ferrick, 1998). The strict relationship between gd
and ab T cells is bidirectional, as demonstrated by the fact that
gd T cell function may depend on ab T cells (Vila et al, 1995;
Burns et al, 1996).
The role of gd T cells in the early anti-tumor defense against
melanoma has been suggested by the evidence that gdTcells may
constitute up to 25% of lymphocyte in¢ltrate in cutaneous
primary melanomas, whereas they are not present in metastatic
melanoma (Bachelez et al, 1992). These cells exert potent cytotoxic
activity against autologous tumor cells (Bachelez et al, 1992;
Nanno et al, 1992). In another study, the survival of patients with
necrotizing choroidal melanomas was increased with evidence
of Vg1 and Vd1 TCRþ cells (Bialasiewicz et al, 1999).
On the basis of the pivotal role that gd T cells may have in the
immune response against melanoma acting directly on tumor
cells and, secondarily, by modulating the phenotype of T cell re-
sponses, we evaluated the peripheral representation and the in vitro
expansion, cytokine production, and cytotoxicity of gd T cells
from melanoma patients, comparing the results with those ob-
tained in healthy controls. This study demonstrated for the ¢rst
time an alteration of circulating gd T cells in melanoma patients,
with a signi¢cant decrease of the number of gd Tcells in the per-
ipheral blood, an altered pattern of cytokine production, and an
impaired in vitro expansion of these cells. The knowledge about
the deterioration of gd T cells could account for the melanoma-
related alterations of T cell-mediated adoptive responses and may
be helpful for the planning of new approaches of immune
therapy in melanoma patients.
MATERIALS AND METHODS
Cell preparation and stimulation Human peripheral blood was
obtained from 23 melanoma patients (mean age7SD 59.6716.1 y;
median: 64.5 y; range 32^80) and 28 healthy subjects (mean age7SD
57.5718.9 y; median: 67.0 y; range 32^79). Healthy subjects were
volunteers in good and stable clinical condition, and had laboratory
parameters in the physiologic range. Melanoma patients have been
admitted to the Dermatology Unit of the I.N.R.C.A. Hospital of Ancona
(Italy). Melanoma patients were in good health other than for the existence
of melanoma as checked on the basis of clinical and laboratory parameters.
Melanoma patients and healthy subjects were equally distributed according
to sex and the percentage of male and female inside each group was about
the same. The investigations were performed after approval by a local
institutional review board. A written informed consent was obtained
from each subject. Diagnosis of melanoma was histologically con¢rmed.
All patients brought cutaneous primary nonmetastatic melanoma and
were staged according to the new American Joint Committee on Cancer
staging system for cutaneous melanoma (Balch et al, 2000). In detail, the
number of patients and the relative tumor thickness was as follows: p1.0
mm (n¼15), 1.01^2.0 mm (n¼ 4), 2.01^4.0 mm (n¼ 2), and p4.0 mm
(n¼ 2). A blood drawing was taken before the surgical excision.
Peripheral blood mononuclear cells (PBMC) were fractionated on
Ficoll-Paque (Pharmacia, Uppsala, Sweden) and separated by density
gradient centrifugation (400 g, 30 min). Cells from the interface of
the gradients were washed twice with Ca2þ and Mg2þ -free phos-
phate-bu¡ered saline (Gibco, Life Technologies, Gaithersburg, MD) and
resuspended in RPMI 1640 supplemented with 10% heat-inactivated fetal
bovine serum, penicillin (100 U per ml) and streptomycin (100 mg per ml)
(all from Life Technologies, complete medium) at a concentration of
1106 per ml. The viability was always greater than 98% as determined
by trypan blue exclusion. Lymphocytes from both melanoma patients and
healthy donors were tested fresh. In each experiment a similar number of
melanoma patients and healthy donors was examined. Each donor was
tested once and all the tests were carried out with a single blood sample.
Mononuclear cells were cultured in the complete medium supplemented
with 100 U per ml of IL-2 (Chiron Milano, Italia). Phosphoantigen-
speci¢c stimulation of gd T cells was performed using the nonpeptidic
antigen isopentenylpyrophosphate (30 mg per ml, IPP; Sigma, St Louis,
MO). After 1 wk of culture, the volume corresponding to half the culture
medium was replaced by fresh medium. On day 10 of culture, viable cells
were counted and used for £uorescence-activated cell sorter analysis and
cytotoxicity. The expansion of gd T cells was followed by cytometric
analysis through double staining of stimulated cells with anti-CD3
[phycoerythrin (PE)] and anti-pan gd, anti-Vd1, or anti-Vd2 T cells
[£uorescein isothiocyanate (FITC)] monoclonal antibody (MoAb). The
absolute number of gd T cells in each culture was calculated as follows:
(percentage of gd T cells among total cells)  (total cell count)/100. The
gd T cell expansion index was then calculated by dividing the absolute
number of gd T cells in stimulated cultures by the absolute number of gd
Tcells before culture (Poccia et al, 1997).
MoAb and £uorescence-activated cell sorter analysis The PE-
conjugated MoAb anti-CD3 was purchased from EuroClone (Devon,
Wetherby, West York, UK). The FITC-conjugated anti-pan-TCR gd, anti-
TCR Vd1, and anti-TCR Vd2 were purchased from Endogen (Boston,
MA). IgG1 (Becton Dickinson Milano, Italy) was used as isotype control.
PBMC (1106) were labeled with 10 ml of anti-CD3 or anti-TCRVd1
MoAb or 5 ml of anti-pan-TCR gd or anti-TCR Vd2 MoAb in a ¢nal
volume of 150 ml of RPMI 1640 with 10% fetal bovine serum for 30 min
in ice. At the end of the incubation, cells were washed in PBS, resuspended
in Isoton II (Coulter, Euro Diagnostics, Hialeah, FL) and immediately
analyzed with a Coulter XL £ow cytometer.
Intracellular detection of IFN-g,TNF-a, and perforin Mononuclear
cells were stimulated with IPP and IL-2 for 18 h, and GolgiPlug (a protein
transport inhibitor containing brefeldin A; PharMingen, Milton Keynes,
U.K.) was added during the last 12 h of culture to block intracellular
transport processes and allow cytokine accumulation. Stimulated cells
(1106) were stained with the anti-pan-TCR gd MoAb for 30 min at
41C. Fixation^permeabilization of cells was performed in PBS/2%
paraformaldehyde for 15 min at 41C, followed by incubation for 30 min
at room temperature in the dark with PE-conjugated anti-human IFN-g
MoAb or anti-human TNF-a MoAb diluted in PBS, 1% bovine serum
albumin, and 0.05% saponin. Cells were ¢nally washed twice in PBS, 1%
bovine serum albumin, and 0.01% saponin and analyzed on a XL £ow
cytometer (Coulter). Perforins were measured after 10 d of incubation
using an anti-human perforin-PE (clone dG9, BD PharMingen) at the
same conditions above reported. The controls for unspeci¢c staining
included incubation with isotype-matched MoAb (PharMingen).
Isolation of gd T lymphocytes and cytotoxic assay gd T
lymphocytes, in vitro expanded with IPP and IL-2 for 10 d, were isolated
through cyto£uorimetric cell sorting (Vantage, Becton Dickinson). The
purity of gd T cells, assessed by cyto£uorimetric analysis, was greater than
95%.
Cytotoxic assay was performed by a £uorimetric method as recently
reported (Provinciali et al, 1992). The natural killer resistant cell line Daudi
and the natural killer cell sensitive K562 cell line were used as target cells.
Daudi is a human lymphoblastoid B cell line derived from a Burkitt
lymphoma, which constitutively expresses antigens recognized by Vd9
Vd2 T cells. K562 is a human myeloid cell line derived from chronic
myelogenous leukemia. The £uorescence was read with a 1420 VICTOR2
multilabel counter (Wallac,Turku, Finland).The percentage of speci¢c lysis
was calculated as follows:
% specific lysis ¼ ½ðFmed  FexpÞ=Fmed100
where F represent the £uorescence of the solubilized cells after the
supernatant has been removed; med¼ F from target incubated in
medium alone; exp¼ F from target incubated with e¡ector cells.
Lytic units (LU20/10
7 cells) were calculated by using a computational
method (Bryant et al, 1992). One LU corresponded to the number of
e¡ector cells required to produce 20% of speci¢c lysis.
Statistical analysis Statistical analysis was performed using parametric
(Student’s t test) or nonparametric (Mann^Whitney rank sum test) tests
on the basis of the distribution of the data. Di¡erence between means
were considered signi¢cant at po0.05. Correlation between gd T cell
number or expansion and tumor thickness was compared by simple linear
regression analysis. The statistical analysis was performed with SigmaStat
software version 1.03 (Jandel Scienti¢c, Erkrath, Germany).
RESULTS
Ex vivo analysis of cd T lymphocytes Peripheral blood
lymphocytes from 23 melanoma patients and 28 healthy subjects
were analyzed for the percentage and the absolute number of gd
T cells through double staining with anti-CD3 and anti-gd
MoAb. As shown in Table I and Fig 1(A), the absolute number
of gd T cells was signi¢cantly reduced in melanoma patients in
comparison with healthy subjects (66.1733.8 vs 92.9732.6;
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po0.01). The absolute number of peripheral lymphocytes was
similar in the two groups of subjects (Table I). As shown in
Fig 1(B), the percentage of CD3þ gd T cells in peripheral
blood was signi¢cantly lower in melanoma patients than in
healthy donors (mean7SD, 3.272.1 vs 4.871.7; po0.01). As
shown in Table I, the absolute number of Vd1 T cells did not
show signi¢cant di¡erence in the two groups of donors
(38.5713.1 and 33.1719.4, in healthy subjects and melanoma
patients, respectively). Di¡erently, the absolute number of Vd2
T cells was signi¢cantly reduced in melanoma patients in
comparison with healthy subjects (31.7713.7 vs 68.2735.8;
po0.01). The Vd2 and Vd1 subsets were di¡erently represented
in the two groups: in healthy controls the Vd2 subset was
predominant (Vd2/Vd1 ratio¼1.8), whereas in melanoma
patients the proportion of Vd2 and Vd1 subsets was similar
(Vd2/Vd1 ratio¼ 0.9) (Table I). No signi¢cant correlation was
found plotting the number of gd T cells and the tumor
thickness of the respective patient.
Cytokine production by cd T lymphocytes As it has been
demonstrated that activated gd T cells produce IFN-g and TNF-
a, we studied the intracellular production of these lymphokines
in 1 d stimulated gd T cells from healthy subjects and melanoma
patients. As shown in Figs 2 and 3, the percentage of gd T cells
producing IFN-g was signi¢cantly reduced in melanoma patients
in comparison with healthy controls (mean7SD, 9.375.5 vs
18.379.5; po0.01). In a similar way, the percentage of gd T cells
producing TNF-a was lower in melanoma patients than in
healthy controls (11.573.8 vs 17.977.7 for melanoma patients and
healthy subjects, respectively; po0.02).
Expansion of cd T lymphocytes The expansion of gd T cells
from healthy controls and melanoma patients was evaluated after
10 d of culture in the presence of IPP and low-dose IL-2. Both
the proportion of gd T cells, evidenced by double staining
£uorescence-activated cell sorter analysis, and their relative
increase in comparison with the gd T cell number found on day
0 (expansion index) were evaluated. As shown in Fig 4, the
proportion of gd T cells reached on day 10 was signi¢cantly
lower in melanoma patients than in healthy donors (mean7SD,
11.978.4 vs 36.5717.6; po0.01). In a similar way, the expansion
index of gd T cells on day 10 vs day 0 was signi¢cantly reduced
in melanoma patients in comparison with healthy controls
(4.473.8 vs 8.676.7; po0.02) (Fig 4). As shown in Table II, the
expansion index of the Vd2 subset was signi¢cantly lower in
melanoma patients than in healthy donors (3.373.6 vs 5.874.4;
po0.03).
Cytotoxicity of cd T lymphocytes In order to evaluate the
cytotoxic potential of gd T cell cultures after in vitro expansion,
we tested the cell activity of gd T cells against Daudi and K562
tumor cell lines and their perforin content through £ow
cytometry. Puri¢ed cultures of activated gd T cells (10 d
incubation), obtained through cyto£uorimetric cell sorting, were
cytotoxic against Daudi tumor cells. A great heterogeneity of
cytotoxic activity was found in both groups considered. Mean
levels of cytotoxicity were similar between healthy subjects and
melanoma patients (438.27141.7 vs 402.57359.2, data not shown).
The cytotoxic activity of gd T cells was also tested against the
K562 tumor cell line, with a similar distribution of cytotoxicity
in normal donors and melanoma patients (data not shown).
The percentage of gd T cells producing perforins among total
gdþ T cells was not signi¢cantly di¡erent in melanoma patients
in comparison with healthy subjects (42.8737.6 vs 51.478.8, data
not shown).
DISCUSSION
In this study we have demonstrated for the ¢rst time the existence
of numerical and functional alterations of gd Tcells from patients
with cutaneous primary melanomas. The number of circulating
gd T cells, the percentage of cells producing IFN-g or TNF-a,
and their in vitro expansion, were all decreased in melanoma pa-
tients when compared with healthy age-matched subjects.
Both the percentage and the absolute number of circulating gd
T cells were signi¢cantly reduced in patients with cutaneous pri-
mary melanoma, thus suggesting a speci¢c de¢cit for this lym-
phocyte population. The reduction of gd T cell number well
Table I. Absolute number of lymphocytes, cdTcells,Vd1 Tcells, and Vd2 Tcells, in healthy subjects and melanoma patients
Absolute no. (nmm3)
Donors Lymphocytes gd T Cells Vd1 T Cells Vd2 T Cells Vd2/Vd1 ratio
Healthy subjects 21597118a 92.9732.6 38.5713.1 68.2735.8 1.8
Melanoma patients 22687539 66.1733.8n 33.1719.4 31.7713.7n 0.9
aData are expressed as mean7SD.
npo0.01 vs healthy subjects.
Figure1. Absolute number and percentage of cd T cells in the per-
ipheral blood of melanoma patients and healthy donors. Freshly iso-
lated PBMC from patients with cutaneous primary melanomas (n¼ 23) or
healthy subjects (n¼ 28) were double stained with MoAb anti-pan gd
(FITC) and anti-CD3 (PE) and analyzed by £ow cytometry. (A) The abso-
lute number of gd Tcells, and (B) the percentage of gd Tcells among total
CD3þ T cells, were both signi¢cantly reduced in melanoma patients in
comparison with healthy subjects (po0.01).
GD T CELLS IN MELANOMA 831VOL. 120, NO. 5 MAY 2003
correlated with the decrease of theVd2 Tcell subset, i.e., the most
frequent subset of circulating gd T cells (Groh et al, 1989; Poccia
et al, 1998). The Vd2 population is involved in the reactivity to-
ward microbial antigens and tumor cell antigens (Poccia et al,
1998; Zheng et al, 2001). The role of Vd2 T cells in the immune
defense against cancer has been demonstrated on the basis of their
reactivity against certain lymphoma cells, such as Daudi cells
(Kunzmann et al, 2000), and for their presence among tumor in-
¢ltrating lymphocytes in various cancer types (Kabelitz et al,
2000). On this basis, our data strongly suggest that an impaired
gd T cell potential may contribute to a lower immune defense
against melanoma. Both Vd1 and Vd2 T cell populations have
been reported to contribute to anti-tumor immunity because of
their cytotoxic and Th1-type cytokines producing activities (Wu
et al, 2002). Furthermore, both gdT cell subsets have been found
able to respond to stress-induced expression of the MHC class I-
related chains A and B (Wu et al, 2002). MHC class I-related
chains function as ligands for NKG2D, an activating receptor
complex that triggers natural killer cells, costimulates CD8 ab
and Vg9d2 gd T cells, and is required for stimulation of Vd1 T
cells (Groh et al, 1999; Das et al, 2001; Girardi et al, 2001;Wu et al,
2002). The role of gd T cells in the early anti-tumor defense
against melanoma has been previously suggested by the evidence
that a signi¢cant accumulation of Vd1 T cells was found in three
of 11 primary cutaneous melanomas, with proportions of gd T
cells ranging from 15 to 25% of lymphocyte in¢ltrate, whereas
gd T cells were not present in eight metastatic melanomas
(Bachelez et al, 1992). In our study, we did not ¢nd numerical
changes of the Vd1 T cell population in melanoma patients in
comparison with controls, whereas the Vd2 subset was signi¢-
cantly reduced in melanoma patients. Almost half of our melano-
ma patients had an absolute number of circulating gd T cells
similar or lower than half of the mean number found in controls
(Fig 1). Phenotypic analysis of the tumor in¢ltrating gd T cells
revealed that they use the products of the Vd9 and Vd2 genes in
a way similar to most of circulating TCR gd. It is noteworthy
that gd lines or clones developed from lymphocytes in¢ltrating
primary melanoma display a potent autologous MHC-unrest-
ricted tumor cell cytotoxicity (Bachelez et al, 1992; Nanno et al,
1992). In a more recent study, the presence of gd T cells well cor-
related with the survival of patients with necrotizing choroidal
melanoma (Bialasiewicz et al, 1999). In our study, not only the
number but also the function of gd Tcells was altered in melano-
ma patients.The in vitro expansion of gd Tcells, that represent one
of the most relevant functional parameters for gdTcells, was sig-
ni¢cantly reduced in patients with cutaneous primary melano-
mas. This would imply that gd T cells from melanoma patients
have a decreased proliferative capacity in comparison with
healthy subjects. Under normal conditions, gdT cells respond to
antigen challenge by secreting large quantities of TNF-a and
IFN-g (Poccia et al, 1997; Kabelitz et al, 2000), which contribute
to the activation of both speci¢c and aspeci¢c immune responses.
In this study, we show that the percentage of gd Tcells producing
either TNF-a or IFN-g is signi¢cantly reduced in melanoma
Figure 2. Analysis of cytokine production by cdTcells in melanoma patients and healthy donors. PBMC from patients with cutaneous primary
melanomas or healthy subjects, were stimulated for 18 h in the presence of IPP (30 mg per ml) and IL-2 (100 U per ml). The last 12 h of culture were
performed in the presence of GolgiPlug, a protein transport inhibitor containing brefeldin. Single-cell analysis of cytokine synthesis in gd T cells from a
representative healthy subject or melanoma patient was performed following dual staining with cell surface anti-gd (FITC) MoAb and intracellular anti-IFNg
or anti- TNF-a (PE) MoAb. Numbers in brackets indicate the percentages of gd cells synthesizing a given cytokine among total gd T lymphocytes.
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patients. Instead, the lytic activity of gd Tcells, evidenced by their
cytotoxicity toward Daudi and K562 tumor cells and their produc-
tion of perforins, seems to be well preserved in melanoma patients.
On the basis of the data reported in this paper, we suggest that
the impairment of gd Tcell number and function may contribute
to the ine⁄cacious immune defense against melanoma with at
least two di¡erent mechanisms. One of these is based on the low-
er gd T cell potential, determined by the reduced number and
expansion of gd T cells, and particularly of Vd2 subset, found in
melanoma patients. In this case, the impairment of gd Tcells may
represent a new mechanism by which melanoma tumor cells es-
cape an e⁄cacious immune response. The second mechanism is
based on the regulatory interactions between gdT cells and ab T
cells. Several studies have demonstrated that the type and the
functioning of the speci¢c lymphocyte response is dependent on
signals provided by the innate recognition system (Fearon and
Locksley, 1996; Medzhitov and Janeway, 1997). Indeed, even if
the recognition of foreign or nonself proteins is controlled by
the rearranging genes that encode speci¢c receptors, the func-
tional outcome of most responses to pathogens and the initiation
of the response itself is determined by the type of innate immune
response they elicit (Fearon and Locksley, 1996; Medzhitov and
Janeway, 1997). Recent evidence has suggested that one of the cru-
cial players involved in the regulation of innate and acquired im-
munity is the gdTcell population (Mak and Ferrick, 1998). There
is substantial cross-talk between gd and ab T cells. It has been
demonstrated that the proliferative response of human peripheral
blood gdTcells towards microbial antigens or Daudi tumor cells,
depends on helper signals provided by CD4þ ab T cells (Burns
et al, 1996a,b). Moreover, some gdT cell function may depend on
ab T cells, as, for example, the gdT cell proliferation in response
to activated CD4þ ab T cells (Burns et al, 1996a,b), and the anti-
gen presentation by CD4þ ab Tcells to gdTcells (Vila et al, 1995;
Collins et al, 1998). On the other hand, substantial evidence has
suggested that gd T cells regulate certain ab T cell-mediated im-
mune responses, pointing the de¢nition of ab T cell responses
toward a Th1 or Th2 phenotype (Fearon and Locksley, 1996;
Mak and Ferrick, 1998; Kabelitz et al, 2000). This fact is particu-
larly related by the cytokines secreted by gdT cells that, in turn,
are able to mediate both innate and acquired immunity (Ferrick
et al, 1995). We propose that, in analogy with what has been
recently demonstrated by us in aged people and centenarians
(Argentati et al, 2002), the numerical and functional impairment
of gd T cells demonstrated in this study could determine a
derangement in the establishment of acquired immunity, with
consequent di⁄culties in selecting appropriate antigens and the
strategies for their elimination. Further studies will be performed
to investigate the speci¢c causes involved in the impairment of gd
T cells in primary cutaneous melanoma patients. At present, we
may only suggest that an impairment of gd T cells may deter-
mine a lower immune defense against melanoma which, in turn,
may predispose to melanoma. The healthy and stable conditions
of melanoma patients examined in this study make improbable
that the gd T cell defect is secondary to the malignancy, even if
this possibility may not be de¢nitively excluded. Finally, the fact
that approximately 10% of patients with melanoma have family
histories of the disease, suggesting a genetic susceptibility (Platz
et al, 1997), raises the question on whether the di¡erences we have
found might be attributable to the genetic background of the
melanoma patients.We do not think this is the case, as melanoma
patients and controls enrolled in our study were identi¢ed in the
Figure 3. Percentage of cd Tcells producing cytokines in melanoma
patients and healthy donors. gdþ T cells from patients with cutaneous
primary melanomas or healthy subjects were activated as reported in Fig 2
and analyzed for cytokine production after dual staining with cell surface
anti-pan gd (FITC) MoAb and intracellular anti-IFN-g or anti-TNF-a (PE)
MoAb.The mean percentage of gd Tcells producing either IFN-g orTNF-
a was signi¢cantly lower in melanoma patients in comparison with healthy
subjects (po0.01 and po0.02 for IFN-g or TNF-a, respectively).
Figure 4. Evaluation of cd T cell expansion in melanoma patients
and healthy donors. PBMC from patients with cutaneous primary mela-
nomas or healthy subjects were stimulated for 10 d in the presence of IPP
(30 mg per ml) and IL-2 (100 U per ml). The expansion index (left panel)
and the percentage (right panel) of in vitro expanded gdþ T cells among
total CD3þ Tcells were signi¢cantly lower in melanoma patients in com-
parison with healthy subjects (po0.02 and po0.01).
Table II. Expansion index of cdTcells and Vd2 Tcells in
healthy subjects and melanoma patients.
Expansion Indexa
Donors gdT cells Vd2 T cells
Healthy subjects 8.676.7b 5.874.4
Melanoma patients 4.473.8n 3.373.6nn
aThe expansion index was calculated by dividing the absolute number of gd T
cells in stimulated cultures by the absolute number of gd T cells before culture.
bData are expressed as mean7SD.
npo0.02 and nnpo0.03 vs healthy subjects.
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same geographical area (Ancona area in Italy), and melanoma pa-
tients did not have family histories of melanoma.
In conclusion, the demonstration of a numerical and functional
derangement of gd Tcells, which we have found in patients with
cutaneous primary melanomas, make them a potentially useful
tool for the planning of new approaches of immune therapy in
malignant melanoma.
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